Statistical Methods. All subjects who are randomized, take one or more doses of test material and have at least one post treatment efficacy measurement will be included in the analysis. Comparisons between treatments will be assessed using an *** with factors of ***, *** and *** and with *** for percent weight loss, and *** for percentage of subjects with at least 5% weight loss. A step-down multiple comparison procedure will be used to compare each dose group with ***. That is, comparison with *** will start at the ***. If the statistical test is significant at *** for both co-primary endpoints, then the test will proceed to the *** also at the ***. If the statistical comparison is not significant at the ***, then the statistical test will be stopped and the *** will not be tested. If both dose groups are significantly better than ***, then the two active dose groups will be compared. A *** of difference in response rate between treatment groups will be derived. The *** for subjects who discontinue treatment prior to completion of the study, ***. INTERNAL PROTOCOL APPROVAL 2 PRINCIPAL INVESTIGATOR SIGNATURE 3 PROTOCOL SYNOPSIS 4
Appears in 1 contract
Statistical Methods. All subjects who are randomized, take one or more doses of test material and have at least one post treatment efficacy measurement will be included in the analysis. Comparisons between treatments will be assessed using an a *** with factors of ***, *** and *** and with *** for percent weight loss, and by *** for percentage percent of subjects with achieving at least 5% weight loss. A step-down multiple comparison procedure will be used to compare each dose group with ***. That is, comparison with *** will start at the ***. If the statistical test is significant at *** for both co-primary endpoints, then the test will proceed to the *** also at the ***. If the statistical comparison is not significant at the ***, then the statistical test will be stopped and the *** will not be tested. If both dose groups are significantly better than ***, then the two active dose groups will be compared. A *** of difference in response rate between treatment groups will be derived. The *** for subjects who discontinue treatment prior to completion of the study, ***. INTERNAL PROTOCOL APPROVAL 2 PRINCIPAL INVESTIGATOR SIGNATURE 3 PROTOCOL SYNOPSIS 44 TABLE OF CONTENTS 7 1 INTRODUCTION 13 1.1 Background 13 1.2 Rationale 14 2 TRIAL OBJECTIVES 14 3 TRIAL DESIGN 14 4 SUBJECT SELECTION 16
Appears in 1 contract